T-Knife Therapeutics is developing novel T cell engineered therapeutics to fight cancer. T cell receptor (TCR) engineered T cells are a promising new therapeutic modality. T-Knife is discovering high affinity and high specificity human TCRs that can be used to supercharge T cells. Through the use of natural, fully human TCRs and tailored armoring, T-Knife’s product candidates are designed to optimize the immune signaling cascade to drive potent T cell responses against tumors. T-Knife’s pipeline includes TCR therapies that target tumor antigens in multiple, difficult to treat solid tumor indications.

T-Knife Therapeutics

T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer 

T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer - GlobeNewswire

T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting - GlobeNewswire

T-knife Therapeutics Announces the Appointment of Donald Wuchterl as Senior Vice President and Chief Manufacturing Officer

T-knife Therapeutics to Participate in Two Investor Conferences in March

T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel - GlobeNewswire

T-knife Therapeutics to Participate in Two Investor Conferences in March - GlobeNewswire

Thank you Brad Loncar for speaking with our team about the innovative TCR-T therapy that T-knife is advancing towards the clinic and the exciting data being generated in the field of T cell therapies that are benefiting patients with cancer.

Donna Osburn - Vacaville Reporter

T-knife Therapeutics Appoints Peggy Sotiropoulou, Ph.D. as Chief Scientific Officer

T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of Directors - GlobeNewswire

T-knife Therapeutics bags $110M to sharpen solid tumor cell therapy push into the clinic - Fierce Biotech

With help from mice, German-born cancer biotech raises $110M, sets up Bay Area home - The Business Journals

Will you be in Miami for the Leerink Global Healthcare Conference? Our CEO Tom Soloway, CFO/CBO Camille Landis, and CSO Peggy Sotiropoulou will be on the ground meeting with investors. Contact us to connect: https://lnkd.in/eSMYVsWE

T-knife Therapeutics Announces Five Presentations at - GlobeNewswire

T-knife Therapeutics Announces New TCR-T Program Targeting - GlobeNewswire

Kite’s head of research leaves for Flagship startup Sonata - Endpoints News

Our CTO Elisa Kieback will be giving a presentation at the LSX World Congress discussing TK-6302, our PRAME targeting TCR-T therapy that has been supercharged with next-generation T cell engineering technologies, and the breadth of data supporting its upcoming CTA submission later this year. If you are attending, join her on Tuesday, April 29 at 2:45pm.

T-knife Therapeutics Announces Five Presentations at American Association for Cancer Research (AACR) Annual Meeting

T-knife Therapeutics Announces the Appointment of Megan Baierlein as Chief Operating Officer

On #WorldCancerResearchDay, we want to recognize the scientists who have made important discoveries in our understanding of cancer, resulting in innovative therapeutics that are extending patients’ lives. At T-knife, we are building upon this growing body of knowledge to develop Supercharged T cell therapies to treat solid tumors.

T-knife Therapeutics bags $110M to sharpen solid tumor ...

At #AACR25, we are presenting multiple datasets demonstrating the best-in-class potential of TK-6302, T-knife’s PRAME targeted TCR-T therapy designed for broad, deep and durable responses in hard-to-treat solid tumor indications. Read the press release summarizing our leading science at https://lnkd.in/eHpapqRB, and follow this link https://lnkd.in/e_C7EBmz to see newly presented videos of TK-6302 eliminating cancer cells in a complex 3D tumor spheroid model. 

We are joining over 3,700 life science leaders at the #BIOEuropeSpring meeting this week to engage on the rapid innovation happening at T-knife and in the field. If you could like to connect with Elisa Kieback and Gloria Kraus, reach out! 

These photos capture the calm before the (fun) storm… Thank you to everyone who visited our five poster presentations at #AACR25. Our presenters were overwhelmed with attendees interested in our PRAME-targeted TCR-T therapy, TK-6302, and our proprietary next-generation technologies for supercharged T cell therapies. If you missed our posters, visit: https://lnkd.in/eTPB2mXz 
Thank you to Marleen Van Loenen, Lucia Poncette, and Peggy Sotiropoulou for expertly communicating our exciting science!

Our CTOO Simone Steiner will be sharing her technical development and manufacturing expertise in three speaking engagements at the Advanced Therapies Europe conference in Lisbon, Portugal this week. If you would like to meet with her, contact us: https://lnkd.in/eSMYVsWE #ATE24 #AdvancedTherapies #Biotech

We recognize our LGBTQI+ family, friends, colleagues and community members this month and every month as we celebrate the power of expression and diversity. #PrideMonth

T-knife Therapeutics Appoints Megan Baierlein as Chief Operating Officer - citybiz

T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Our CEO Tom Soloway and CFO/CBO Camille Landis will be in Miami starting tomorrow to participate in the Evercore HealthCONx Conference. If you are in town and would like to connect, contact us: https://lnkd.in/eSMYVsWE

T-knife Therapeutics Appoints Biotech Industry Veteran Laura Brege to its Board of Directors

T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting

Chutes & Ladders—Gene editing biotech Metagenomi adds CSO, CFO - Fierce Biotech

At the TCR Summit, our CSO Peggy Sotiropoulou will review how we are developing supercharged TCR-Ts that incorporate multiple best-in-class technologies, including armoring techniques that aim to fortify TCR-T cells. Conference info: https://lnkd.in/gF2zkg8 

T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer - GlobeNewswire

People - Nature.com

The CAR-TCR Summit Series is a premier conference bringing together industry leaders to review scientific and technical progress and data on T-cell based therapies. At next week’s conference, our CTO Elisa Kieback and CSO Peggy Sotiropoulou will share insights based on our leading platform for T cell receptor engineered T cell therapies (TCR-Ts). #CARTCR 

T-knife—unleashing T-cell receptors on cancer - Nature

T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T

T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies - GlobeNewswire

Congratulations to our friends at Adaptimmune on this incredible achievement! Their first-in-class approval of Tecelra provides an important new therapy for patients living with synovial sarcoma, and it is a landmark milestone for the field of solid tumor focused cell therapies.

T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel

T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of Directors

Our CTO and co-founder, Elisa Kieback, will be presenting at the #BIOEuropeSpring Conference on March 19th in Barcelona, Spain. If you’re attending, we hope to see you there! https://lnkd.in/eRdjEqv 

T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting - Yahoo Finance

Chutes & Ladders—Former Roche pharma chief tapped to be new Bayer CEO - Fierce Biotech

We are excited to be presenting five posters at #AACR25 highlighting our proprietary next-generation technologies for T cell receptor therapies demonstrating differentiated T cell fitness, persistence and effectiveness! https://lnkd.in/edfhciKV

Our CEO Tom Soloway, CFO/CBO Camille Landis, and CTO Elisa Kieback are off to Boston next week for meetings at the TD Cowen Annual Health Care Conference. If you would like to connect, reach out to us here: https://lnkd.in/eSMYVsWE

T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting

T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial 

T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy  

T-knife Therapeutics Presents Preclinical Data at the - GlobeNewswire

T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting

T-knife will be presenting our supercharged TCR-T technologies and discussing the overall oncology landscape at the BIO International Convention. If you will be in San Diego, contact us to meet: https://lnkd.in/eSMYVsWE

Our Co-founder and CTO Elisa Kieback, Ph.D., will present at the 25th #BioEquityEurope conference in Bruges, Belgium on Wednesday, May 14, 2025 at 9:30 a.m. CEST. 
  
If you're attending, don’t miss the chance to hear how T-knife has developed the next generation of TCR-based cell therapies, unlocking the potential for broad, deep and durable responses in solid tumors — a bold step forward in the fight against cancer.
 
Learn more about the conference: https://bit.ly/3M8fiB4
 
#TCellEngineering #BioEquity2025

Join our Head of Cell Therapy Manufacturing Ute Brassat for an informative presentation as she shares her expertise in effectively selecting and engaging with the right CDMO @ the Supply Chain & Logistics for Cell & Gene Therapies Summit in Boston this week.

T-Knife Therapeutics

Business:

Drug notes:

About: